CoChat
Sign Up
Cited by 142Muscle Physiology and DisordersNutrition and Health in AgingSirtuins and Resveratrol in Medicine

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

Myricanol rescues dexamethasone-induced muscle dysfunction Via a sirtuin 1-dependent mechanism

Open access
Shen, Shengnan, Liao, Qiwen, Liu, Jingxin, Pan, Ruile, Lee, Simon Ming‐Yuen, Lin, Ligen·2019·Journal of Cachexia Sarcopenia and Muscle
DOI 10.1002/jcsm.12393PMC PMC6463464
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Muscle atrophy and weakness are adverse effects of high dose or the sustained usage of glucocorticoids. Loss of mitochondria and degradation of protein are highly correlated with muscle dysfunction. The deacetylase sirtuin 1 (SIRT1) plays a vital role in muscle remodelling. The current study was designed to identify myricanol as a SIRT1 activator, which could protect skeletal muscle against dexamethasone-induced wasting. METHODS: The dexamethasone-induced atrophy in C2C12 myotubes was evaluated by expression of myosin heavy chain, muscle atrophy F-box (atrogin-1), and muscle ring finger 1 (MuRF1), using western blots. The mitochondrial content and oxygen consumption were assessed by MitoTracker staining and extracellular flux analysis, respectively. Muscle dysfunction was established in male C57BL/6 mice (8-10 weeks old, n = 6) treated with a relatively high dose of dexamethasone (25 mg/kg body weight, i.p., 10 days). Body weight, grip strength, forced swimming capacity, muscle weight, and muscle histology were assessed. The expression of proteolysis-related, autophagy-related, apoptosis-related, and mitochondria-related proteins was analysed by western blots or immunoprecipitation. RESULTS: Myricanol (10 μM) was found to rescue dexamethasone-induced muscle atrophy and dysfunction in C2C12 myotubes, indicated by increased expression of myosin heavy chain (0.33 ± 0.14 vs. 0.89 ± 0.21, *P < 0.05), decreased expression of atrogin-1 (2.31 ± 0.67 vs. 1.53 ± 0.25, *P < 0.05) and MuRF1 (1.55 ± 0.08 vs. 0.99 ± 0.12, **P < 0.01), and elevated ATP production (3.83 ± 0.46 vs. 5.84 ± 0.79 nM/mg protein, **P < 0.01), mitochondrial content (68.12 ± 10.07% vs. 116.38 ± 5.12%, *P < 0.05), and mitochondrial oxygen consumption (166.59 ± 22.89 vs. 223.77 ± 22.59 pmol/min, **P < 0.01). Myricanol directly binds and activates SIRT1, with binding energy of -5.87 kcal/mol. Through activating SIRT1 deacetylation, myricanol inhibits forkhead box O 3a transcriptional activity to reduce protein degradation, induces autophagy to enhance degraded protein clearance, and increases peroxisome proliferator-activated receptor γ coactivator-1α activity to promote mitochondrial biogenesis. In dexamethasone-induced muscle wasting C57BL/6 mice, 5 mg/kg myricanol treatment reduces the loss of muscle mass; the percentages of quadriceps and gastrocnemius muscle in myricanol-treated mice are 1.36 ± 0.02% and 0.87 ± 0.08%, respectively (cf. 1.18 ± 0.06% and 0.78 ± 0.05% in dexamethasone-treated mice, respectively). Myricanol also rescues dexamethasone-induced muscle weakness, indicated by improved grip strength (70.90 ± 4.59 vs. 120.58 ± 7.93 g, **P < 0.01) and prolonged swimming exhaustive time (48.80 ± 11.43 vs. 83.75 ± 15.19 s, **P < 0.01). Myricanol prevents dexamethasone-induced muscle atrophy and weakness by activating SIRT1, to reduce muscle protein degradation, enhance autophagy, and promote mitochondrial biogenesis and function in mice. CONCLUSIONS: Myricanol ameliorates dexamethasone-induced skeletal muscle wasting by activating SIRT1, which might be developed as a therapeutic agent for treatment of muscle atrophy and weakness.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/jcsm.12393

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 MY rescues DEX‐induced muscle atrophy in C2C12 myotubes. (A) Chemical structure of MY. (B) Cell viability of C2C12 myotubes treated with DEX and different concentrations of MY. (C) Expression levels of MyHC, atrogin‐1, and MuRF1. GAPDH was used as a loading control. Data are shown as mean ± SD, n = 6–9. *P < 0.05, **P < 0.01, MY vs. DEX. # P < 0.05, ## P < 0.01, control vs. DEX. DEX, dexamethasone; MuRF1, muscle ring finger 1; MY, myricanol; MyHC, myosin heavy chain.
Figure 1 MY rescues DEX‐induced muscle atrophy in C2C12 myotubes. (A) Chemical structure of MY. (B) Cell viability of C2C12 myotubes treated with DEX and different concentrations of MY. (C) Expression levels of MyHC, atrogin‐1, and MuRF1. GAPDH was used as a loading control. Data are shown as mean ± SD, n = 6–9. *P < 0.05, **P < 0.01, MY vs. DEX. # P < 0.05, ## P < 0.01, control vs. DEX. DEX, dexamethasone; MuRF1, muscle ring finger 1; MY, myricanol; MyHC, myosin heavy chain.CC BY-NC · PubMed Central
Figure 2 MY protects against DEX‐induced muscle atrophy through activating SIRT1. (A) MY increased SIRT1 expression dose‐dependently in DEX‐treated C2C12 myotubes. (B) Interactive sites between MY and SIRT1 by docking analysis. (C) MY enhanced SIRT1 deacetylase activity in C2C12 myotubes. (D) EX‐527 almost reversed MY‐induced changes of SIRT1, MuRF1, and atrogin‐1 expression in DEX‐treated myotubes. (E) MY increased phosphorylation of Akt and FoxO3a in DEX‐treated C2C12 myotubes. GAPDH was used as a loading control. Data are shown as mean ± SD, n = 6–9. *P < 0.05, **P < 0.01, MY or EX‐527 vs. DEX. ## P < 0.01, control vs. DEX. DEX, dexamethasone; MY, myricanol; SIRT1, sirtuin 1.
Figure 2 MY protects against DEX‐induced muscle atrophy through activating SIRT1. (A) MY increased SIRT1 expression dose‐dependently in DEX‐treated C2C12 myotubes. (B) Interactive sites between MY and SIRT1 by docking analysis. (C) MY enhanced SIRT1 deacetylase activity in C2C12 myotubes. (D) EX‐527 almost reversed MY‐induced changes of SIRT1, MuRF1, and atrogin‐1 expression in DEX‐treated myotubes. (E) MY increased phosphorylation of Akt and FoxO3a in DEX‐treated C2C12 myotubes. GAPDH was used as a loading control. Data are shown as mean ± SD, n = 6–9. *P < 0.05, **P < 0.01, MY or EX‐527 vs. DEX. ## P < 0.01, control vs. DEX. DEX, dexamethasone; MY, myricanol; SIRT1, sirtuin 1.CC BY-NC · PubMed Central
Figure 3 MY reverses DEX‐induced loss of mitochondrial content and function in C2C12 myotubes. (A) MY increased mitochondrial content in DEX‐treated C2C12 myotubes, as assessed by MitoTracker Green staining. Scale bar = 100 μm. The images were captured using a Leica TCS SP8 Confocal Laser Scanning Microscope System with a 10× objective. (B) The effect of MY on ATP concentration in DEX‐treated C2C12 myotubes. (C) MY increased the expression levels of Cox2, Tom20, UCP3, and PGC‐1α. GAPDH was used as a loading control. (D) MY reversed DEX‐induced decrease of PGC‐1α expression and increase of acetylated PGC‐1α level, which were abolished by co‐treatment of EX‐527. (E) MY reversed DEX‐induced increases of total and acetylated FoxO3a levels, which were abolished by co‐treatment of EX‐527. (F) MY increased OCR in DEX‐treated C2C12 myotubes, as assessed by Seahorse assay. Data are shown as mean ± SD, n = 6–9. *P < 0.05, **P < 0.01, MY vs. DEX. # P < 0.05, ## P < 0.01, control vs. DEX or EX‐527. DEX, dexamethasone; MY, myricanol; OCR, oxygen consumption rate; UCP3, uncoupling protein 3.
Figure 3 MY reverses DEX‐induced loss of mitochondrial content and function in C2C12 myotubes. (A) MY increased mitochondrial content in DEX‐treated C2C12 myotubes, as assessed by MitoTracker Green staining. Scale bar = 100 μm. The images were captured using a Leica TCS SP8 Confocal Laser Scanning Microscope System with a 10× objective. (B) The effect of MY on ATP concentration in DEX‐treated C2C12 myotubes. (C) MY increased the expression levels of Cox2, Tom20, UCP3, and PGC‐1α. GAPDH was used as a loading control. (D) MY reversed DEX‐induced decrease of PGC‐1α expression and increase of acetylated PGC‐1α level, which were abolished by co‐treatment of EX‐527. (E) MY reversed DEX‐induced increases of total and acetylated FoxO3a levels, which were abolished by co‐treatment of EX‐527. (F) MY increased OCR in DEX‐treated C2C12 myotubes, as assessed by Seahorse assay. Data are shown as mean ± SD, n = 6–9. *P < 0.05, **P < 0.01, MY vs. DEX. # P < 0.05, ## P < 0.01, control vs. DEX or EX‐527. DEX, dexamethasone; MY, myricanol; OCR, oxygen consumption rate; UCP3, uncoupling protein 3.CC BY-NC · PubMed Central
Figure 4 Effects of MY on apoptosis and autophagy in DEX‐treated C2C12 myotubes. (A) MY elevated the expression of autophagy‐related proteins LC3 and Beclin1 and suppressed the expression of p62. (B) MY increased lysosome content in DEX‐treated C2C12 myotubes, as assessed by LysoTracker fluorescence staining. Scale bar = 100 μm. The images were captured using a Leica TCS SP8 Confocal Laser Scanning Microscope System with a 10× objective. (C) Expression of apoptosis‐associated proteins, Bcl‐2, Bax, cleaved caspase‐3. GAPDH was used as a loading control. (D) Co‐treatment of EX‐527 abolished the effect of MY on expression of apoptosis‐associated proteins. Data are shown as mean ± SD, n = 6–9. *P < 0.05, **P < 0.01, MY or EX‐527 vs. DEX. ## P < 0.01, control vs. DEX. DEX, dexamethasone; MY, myricanol.
Figure 4 Effects of MY on apoptosis and autophagy in DEX‐treated C2C12 myotubes. (A) MY elevated the expression of autophagy‐related proteins LC3 and Beclin1 and suppressed the expression of p62. (B) MY increased lysosome content in DEX‐treated C2C12 myotubes, as assessed by LysoTracker fluorescence staining. Scale bar = 100 μm. The images were captured using a Leica TCS SP8 Confocal Laser Scanning Microscope System with a 10× objective. (C) Expression of apoptosis‐associated proteins, Bcl‐2, Bax, cleaved caspase‐3. GAPDH was used as a loading control. (D) Co‐treatment of EX‐527 abolished the effect of MY on expression of apoptosis‐associated proteins. Data are shown as mean ± SD, n = 6–9. *P < 0.05, **P < 0.01, MY or EX‐527 vs. DEX. ## P < 0.01, control vs. DEX. DEX, dexamethasone; MY, myricanol.CC BY-NC · PubMed Central
Figure 5 MY protects against DEX‐induced muscle dysfunction in mice. (A) Body weight. [two‐way ANOVA: time effect F (10, 180) = 60.98, P < 0.0001; treatment effect F (6, 18) = 11.96, P < 0.0001; interaction F (60, 180) = 11.26, P < 0.0001]. (B) Grip strength. [two‐way ANOVA: time effect F (5, 140) = 81.00, P < 0.0001; treatment effect F (7, 28) = 152.00, P < 0.0001; interaction F (35, 140) = 6.40, P < 0.0001]. (C) Forced swimming time. (D) Comparison of representative samples of dissected skeletal muscle, including Gast, soleus, EDL, Quad, and TA. (E) The ratios of Gast and Quad muscle weight to body weight. (F) Representative H&E staining of myofiber cross section of Gast. Scale bar = 100 or 50 μm on top and bottom, respectively. A microscope with a 10× or 20× objective was used to capture the images. (G) The cross‐sectional diameter of Gast muscle fibre. Ctrl: PEG 400 solution; ctrl + MY‐50: PEG 400 solution with 50 mg/kg MY; DEX: PEG 400 solution with 25 mg/kg dexamethasone; DEX + MY‐5: DEX solution with 5 mg/kg MY; DEX + MY‐50: DEX solution with 50 mg/kg MY; DEX + EX‐527: DEX solution with 10 mg/kg EX‐527; DEX + MY‐50 + EX‐527: DEX solution with 50 mg/kg MY and 10 mg/kg EX‐527. Data are shown as mean ± SD, n = 6. *P < 0.05, **P < 0.01, DEX + MY‐5 vs. DEX. & P < 0.05, && P < 0.01, DEX + MY‐50 vs. DEX. # P < 0.05, ## P < 0.01, control vs. DEX. ANOVA, analysis of variance; DEX, dexamethasone; EDL, extensor digitorum longus; Gast, gastrocnemius; MY, myricanol; Quad, quadriceps; TA, tibialis anterior.
Figure 5 MY protects against DEX‐induced muscle dysfunction in mice. (A) Body weight. [two‐way ANOVA: time effect F (10, 180) = 60.98, P < 0.0001; treatment effect F (6, 18) = 11.96, P < 0.0001; interaction F (60, 180) = 11.26, P < 0.0001]. (B) Grip strength. [two‐way ANOVA: time effect F (5, 140) = 81.00, P < 0.0001; treatment effect F (7, 28) = 152.00, P < 0.0001; interaction F (35, 140) = 6.40, P < 0.0001]. (C) Forced swimming time. (D) Comparison of representative samples of dissected skeletal muscle, including Gast, soleus, EDL, Quad, and TA. (E) The ratios of Gast and Quad muscle weight to body weight. (F) Representative H&E staining of myofiber cross section of Gast. Scale bar = 100 or 50 μm on top and bottom, respectively. A microscope with a 10× or 20× objective was used to capture the images. (G) The cross‐sectional diameter of Gast muscle fibre. Ctrl: PEG 400 solution; ctrl + MY‐50: PEG 400 solution with 50 mg/kg MY; DEX: PEG 400 solution with 25 mg/kg dexamethasone; DEX + MY‐5: DEX solution with 5 mg/kg MY; DEX + MY‐50: DEX solution with 50 mg/kg MY; DEX + EX‐527: DEX solution with 10 mg/kg EX‐527; DEX + MY‐50 + EX‐527: DEX solution with 50 mg/kg MY and 10 mg/kg EX‐527. Data are shown as mean ± SD, n = 6. *P < 0.05, **P < 0.01, DEX + MY‐5 vs. DEX. & P < 0.05, && P < 0.01, DEX + MY‐50 vs. DEX. # P < 0.05, ## P < 0.01, control vs. DEX. ANOVA, analysis of variance; DEX, dexamethasone; EDL, extensor digitorum longus; Gast, gastrocnemius; MY, myricanol; Quad, quadriceps; TA, tibialis anterior.CC BY-NC · PubMed Central
Figure 6 Western blotting analysis of key proteins in Gast muscle. (A) The expression of SIRT1, atrogin‐1, MuRF1, phosphorylated Akt, total Akt, phosphorylated FoxO3a, and total FoxO3a. (B) The expression of LC3, Beclin1, p62, cleaved caspase‐3, Bcl‐2, and Bax. (C) The expression of PGC‐1α, Tom20, UCP3, and Cox2. β‐actin was used as a loading control. Data are shown as mean ± SD, n = 6. *P < 0.05, **P < 0.01, DEX + MY‐5 vs. DEX. & P < 0.05, && P < 0.01, DEX + MY‐50 vs. DEX. # P < 0.05, ## P < 0.01, control vs. DEX. DEX, dexamethasone; MuRF1, muscle ring finger 1; MY, myricanol; SIRT1, sirtuin 1; UCP3, uncoupling protein 3.
Figure 6 Western blotting analysis of key proteins in Gast muscle. (A) The expression of SIRT1, atrogin‐1, MuRF1, phosphorylated Akt, total Akt, phosphorylated FoxO3a, and total FoxO3a. (B) The expression of LC3, Beclin1, p62, cleaved caspase‐3, Bcl‐2, and Bax. (C) The expression of PGC‐1α, Tom20, UCP3, and Cox2. β‐actin was used as a loading control. Data are shown as mean ± SD, n = 6. *P < 0.05, **P < 0.01, DEX + MY‐5 vs. DEX. & P < 0.05, && P < 0.01, DEX + MY‐50 vs. DEX. # P < 0.05, ## P < 0.01, control vs. DEX. DEX, dexamethasone; MuRF1, muscle ring finger 1; MY, myricanol; SIRT1, sirtuin 1; UCP3, uncoupling protein 3.CC BY-NC · PubMed Central
Figure 7 Schematic models of molecular targets of MY in DEX‐induced muscle atrophy. DEX, dexamethasone; MY, myricanol.
Figure 7 Schematic models of molecular targets of MY in DEX‐induced muscle atrophy. DEX, dexamethasone; MY, myricanol.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 64 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Shen, S., Liao, Q., Liu, J., Pan, R., Lee, S. M., & Lin, L.
Affiliations
  • University of Macau (MO)
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Corresponding author
Lin, Ligen
ORCID
Venue
Journal of Cachexia Sarcopenia and Muscle
Publisher
Wiley
Published
2019-02-21
Volume
10
Issue
2
Pages
429-444
ISSN
  • 2190-5991 (ISSN-L)
  • 2190-6009
DOI
10.1002/jcsm.12393
PMC
PMC6463464
OpenAlex
W2915142269
Cited by
142
References
64
Citations by year
2026: 15 · 2025: 22 · 2024: 34 · 2023: 19 · 2022: 19 · 2021: 15 · 2020: 14 · 2019: 4
FWCI
4.30
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Cachexia Sarcopenia and Muscle (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China (81872754)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
  • Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
Keywords
dexamethasone, glucocorticoid-induced muscle atrophy, skeletal muscle dysfunction, SIRT1, mitochondrial function, mitochondrial oxygen consumption, atrogin-1, MuRF1, ubiquitin ligase, muscle protein degradation, autophagy, apoptosis, myosin heavy chain, muscle strength
MeSH terms
Animals, Autophagy, Organelle Biogenesis, Cell Line, Dexamethasone, Disease Models, Animal, Gene Expression Regulation, Models, Molecular, Molecular Conformation, Muscular Atrophy, Structure-Activity Relationship, Biomarkers, Apoptosis, Muscle, Skeletal, Muscle Fibers, Skeletal, Diarylheptanoids, Mice, Sirtuin 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review